REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

NASDAQ:RVPH • US76152G1004

0.247 USD
-0.01 (-2.95%)
At close: Feb 20, 2026
0.25 USD
+0 (+1.21%)
After Hours: 2/20/2026, 8:03:55 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall RVPH gets a fundamental rating of 1 out of 10. We evaluated RVPH against 193 industry peers in the Pharmaceuticals industry. The financial health of RVPH is average, but there are quite some concerns on its profitability. RVPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year RVPH has reported negative net income.
  • RVPH had a negative operating cash flow in the past year.
  • In the past 5 years RVPH reported 4 times negative net income.
  • In the past 5 years RVPH always reported negative operating cash flow.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -158.77%, RVPH is not doing good in the industry: 86.91% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -500.18%, RVPH is doing worse than 80.63% of the companies in the same industry.
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RVPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • RVPH has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RVPH has been increased compared to 5 years ago.
  • The debt/assets ratio for RVPH is higher compared to a year ago.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -20.80, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
  • RVPH has a Altman-Z score of -20.80. This is amonst the worse of the industry: RVPH underperforms 83.77% of its industry peers.
  • There is no outstanding debt for RVPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.8
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.39 indicates that RVPH should not have too much problems paying its short term obligations.
  • The Current ratio of RVPH (1.39) is worse than 73.30% of its industry peers.
  • A Quick Ratio of 1.39 indicates that RVPH should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.39, RVPH is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • RVPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.56%, which is quite impressive.
EPS 1Y (TTM)58.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RVPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.62% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.91%
EPS Next 2Y28.68%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RVPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RVPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RVPH's earnings are expected to grow with 18.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.68%
EPS Next 3Y18.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RVPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (2/20/2026, 8:03:55 PM)

After market: 0.25 +0 (+1.21%)

0.247

-0.01 (-2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners8.22%
Inst Owner Change32.6%
Ins Owners3.01%
Ins Owner Change0%
Market Cap28.86M
Revenue(TTM)N/A
Net Income(TTM)-22.76M
Analysts81.54
Price Target5.67 (2195.55%)
Short Float %21.16%
Short Ratio4.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.25%
Min EPS beat(2)-6.95%
Max EPS beat(2)39.44%
EPS beat(4)3
Avg EPS beat(4)23.56%
Min EPS beat(4)-6.95%
Max EPS beat(4)39.44%
EPS beat(8)7
Avg EPS beat(8)18.04%
EPS beat(12)8
Avg EPS beat(12)-2.4%
EPS beat(16)11
Avg EPS beat(16)0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.26%
PT rev (3m)29.79%
EPS NQ rev (1m)15.15%
EPS NQ rev (3m)34.27%
EPS NY rev (1m)2.37%
EPS NY rev (3m)11.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.34
P/tB 6.34
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -20.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y55.91%
EPS Next 2Y28.68%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.57%
OCF growth 3YN/A
OCF growth 5YN/A

REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ

Can you provide the ChartMill fundamental rating for REVIVA PHARMACEUTICALS HOLDI?

ChartMill assigns a fundamental rating of 1 / 10 to RVPH.


What is the valuation status of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

ChartMill assigns a valuation rating of 0 / 10 to REVIVA PHARMACEUTICALS HOLDI (RVPH). This can be considered as Overvalued.


What is the profitability of RVPH stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a profitability rating of 0 / 10.